We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Turing Pharmaceuticals has flip-flopped on its decision to reduce the list price of Daraprim, instead offering discounts of up to 50 percent to hospitals, as well as other minor adjustments to help patients afford the drug, which has skyrocketed in price from $13.50 a pill to $750. Read More
Par Pharmaceutical’s efforts to litigate its way to a generic version of Adderall XR ended with a whimper Tuesday, after a federal judge barred the company from challenging Shire’s patents on the drug. Read More
A Merck subsidiary could lose patent protection on the popular antibiotic Cubicin next year, after a federal appellate court invalidated four of the company’s five patents on the drug. Read More
The U.S. Supreme Court has refused to hear patent infringement cases brought by two drugmakers against Apotex, paving the way for the Canadian company to produce a generic version of Benicar. Read More